Nyxoah SA (FRA:5YI)
€ 1.228 +0.014 (+1.15%) Market Cap: 136.90 Mil Enterprise Value: 146.04 Mil PE Ratio: 0 PB Ratio: 1.70 GF Score: 65/100

Nyxoah SA at JPMorgan Healthcare Conference Transcript

Jan 15, 2026 / 08:00PM GMT
Release Date Price: €4.32 (+0.82%)
Varun Srivastava
JPMorgan - Analyst

Good morning, everyone, and welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Varun, and it is my pleasure to invite on stage today Nyxoah, represented by their CEO, Olivier Taelman.

Please put your hands together for Olivier.

Olivier Taelman
Nyxoah SA - Chief Executive Officer, Executive Director

Thank you. Let me start by thanking JPMorgan for the invitation. My name is Olivier Taelman. I am the CEO of Nyxoah. Nyxoah, a medtech company offering an innovative solution by neurostimulation to help patients suffering from obstructive sleep apnea.

We are listed on both Nasdaq and Euronext under the ticker NYXH. Currently, we are going through the most exciting time in company history since we have obtained in August last year FDA approval, and we are actively launching our product to help patients in the US, suffering from obstructive sleep apnea. Our vision is to make sleep simple.

Now before I will walk you through the technology, the commercial updates, et cetera, I would

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot